Riskpilot← Back to searchSign inGet full accessNORDIC BIOSCIENCE HOLDING A/S
A/SActiveCVR 30511271Herlev Hovedgade 205Activities of holding companies · NACE 6421Est. 20071 employeeswww.nordicbioscience.com
Revenue 2024
DKK 527,4M
EBITDA margin
37.5%
+21927% vs 2023
Equity ratio
32.1%
Financial strength
Net profit 2024
DKK 170,8M
+904% vs 2023
| Revenue | DKK 527,4M | — |
| EBITDA | DKK 197,7M | +21927% |
| Net profit | DKK 170,8M | +904% |
| Total assets | DKK 720,3M | +279% |
| Equity | DKK 230,9M | +373% |
| Employees | 1 | — |
Legal name
NORDIC BIOSCIENCE HOLDING A/S
CVR number
30511271
Legal form
Aktieselskab
NACE code
6421 · Activities of holding companies
Founded
29. juni 2007
Share capital
DKK 10.616.384
Employees
1 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af formanden i forening med en direktør, af tre bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed indenfor bioteknologi og anden dermed i forbindelse stående virksomhed, herunder udvikling, produktion og salg af diagnostiske kit samt eje datterselskaber i forbindelse hermed.
Address
Herlev Hovedgade 205
Phone
+4544525252
Email
info@nordicbio.com
Website
www.nordicbioscience.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | -49 | -7.474 | 111.792 | 0 | — | — | — | — | — | — | — | 0 | 527.393 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1.949 | -3.284 | -2.602 | -1.184 | -0 | -0 | -0 | -840 | -0 |
| EBITDA | — | — | — | — | -49 | 2.420 | 47.983 | -1.273 | -1.996 | -3.345 | -2.683 | -1.360 | -239 | -1.454 | -1.025 | -906 | 197.729 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -9.894 | -9.567 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | — | — | — | — | -49 | -7.474 | 38.416 | -1.273 | -1.996 | -3.345 | -2.683 | -1.360 | -239 | -1.454 | -1.025 | -906 | 197.729 |
| Net financials | 0 | 0 | 0 | 0 | -62.059 | 112.311 | 12.201 | 39.411 | 12.530 | 295.511 | 36.017 | 108.663 | 80.218 | 49.364 | 50.666 | 18.338 | 16.077 |
| Profit before tax | — | — | — | — | -62.108 | 104.837 | 50.617 | 38.138 | 10.534 | 292.166 | 33.334 | 107.302 | 79.979 | 47.911 | 49.641 | 17.432 | 209.806 |
| Tax | -0 | -0 | -0 | -0 | 1.367 | 6.319 | 10.177 | 5.010 | 7.319 | 2.438 | -4.921 | -2.609 | 93 | -4.373 | -1.963 | 422 | 38.993 |
| Net profit | — | — | — | — | -63.475 | 98.518 | 40.440 | 33.128 | 3.215 | 289.728 | 38.255 | 109.912 | 79.886 | 52.284 | 51.604 | 17.010 | 170.813 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 0 | 230.020 | 337.244 | 362.590 | 323.689 | 369.388 | 897.491 | 503.165 | 488.879 | 363.237 | 300.395 | 227.119 | 190.248 | 720.316 |
| Equity | — | — | — | — | 217.493 | 239.434 | 278.755 | 310.479 | 316.661 | 597.473 | 237.840 | 282.390 | 136.416 | 118.494 | 62.431 | 48.802 | 230.949 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 20.854 | 23.314 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40.647 |
| Short-term debt | 0 | 0 | 0 | 0 | 1.443 | 76.956 | 60.521 | 268 | 52.727 | 300.018 | 265.325 | 206.489 | 226.821 | 181.901 | 164.687 | 141.447 | 448.721 |
| Total debt | 0 | 0 | 0 | 0 | 1.443 | 97.810 | 83.835 | 268 | 52.727 | 300.018 | 265.325 | 206.489 | 226.821 | 181.901 | 164.687 | 141.447 | 489.367 |
EBITDA margin
37.5%
This company
15.8%
Market median
+137% vs market
20082024
Equity ratio
32.1%
This company
38.2%
Market median
+16% vs market
20082024
Return on equity
74.0%
This company
18.4%
Market median
+302% vs market
20082024
Net profit margin
32.4%
This company
8.1%
Market median
+300% vs market
20082024
Asset turnover
0.73×
This company
1.12×
Market median
-35% vs market
20082024
Debt / equity
2.12×
This company
0.62×
Market median
-242% vs market
20082024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via CVR / Virk · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via CVR / Virk · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via CVR / Virk · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via CVR / Virk · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TN Founder | Founder | 2007 | — | — |
MA Management | Management | 2010 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2007 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2011 | — | — | |
| Deputy Chairman | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Romarine ApS | Company | 66.7% | 66.7% | 2021 |
| Individual | 10.0% | 10.0% | 2021 | |
Nordic Life Science Consulting ApS | Company | 5.0% | 5.0% | 2024 |
| Individual | 33.3% | 33.3% | 2015 | |
NORDIC BIOSCIENCE HOLDING A/S | Company | 20.0% | 20.0% | 2013 |
C.C. CONSULTING A/S | Company | 66.7% | 66.7% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nordic Life Science Consulting ApS
NORDIC BIOSCIENCE HOLDING A/S Board members of NORDIC BIOSCIENCE HOLDING A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Nielsen | Founder | 0 companies |
| Morten Asser Karsdal | Management | 0 companies |
| Peter Degnboel Thostrup | Chairman | 0 companies |
| Herbert Schmidt | Board of Directors | 0 companies |
| Peter Severini | Board of Directors | 0 companies |
| Kugan Sathiyanandarajah | Board of Directors | 0 companies |
| David H Mac Callum | Board of Directors | 0 companies |
| Hervé Girsault | Board of Directors | 0 companies |
| Niels Lolk Helveg Petersen | Board of Directors | 0 companies |
| Henrik Bernt Sanders | Board of Directors | 0 companies |
| Steffen Kragh | Deputy Chairman | 0 companies |
| Claus Henrik Christiansen | Board of Directors | 0 companies |
| Anders Bengt Martin Borg | Board of Directors | 0 companies |
| Sven Håkan Björklund | Chairman | 0 companies |